Related by context. All words. (Click for frequent words.) 72 p = 71 p = #.# [002] 71 randomized 70 P = .# 68 ≥ 68 % CI #.#-#.# [002] 67 p = #.# [004] 67 % CI #.#-#.# [003] 67 % CI #.#-#.# [006] 67 mg kg 66 confidence interval CI 66 evaluable 65 mg BID 65 mg kg dose 64 mcg kg 64 CI = 64 mcg BID 64 placebo 64 #mg QD [002] 63 normotensive 63 atazanavir ritonavir 63 % CI #.#-#.# [007] 63 ± 63 postoperatively 63 mg QD 63 mg d 62 mcg QD 62 undetectable HBV DNA 62 posttreatment 62 lopinavir r arm 62 #mg QD [001] 62 randomly assigned 62 seronegative 62 % CI #.#-#.# [008] 62 confidence interval #.#-#.# 62 #mg/day [001] 62 postintervention 62 p = NS 61 mcg albinterferon alfa 2b 61 REYATAZ r arm 61 prospective cohort 61 μg 61 aged ≥ 61 ± SD 61 randomized #:# 61 4mg/kg 61 mg TID 61 lopinavir r 61 evaluable patients 61 pg mL 61 interquartile range 61 pegylated interferon alfa 2b 61 mg/m2 dose 61 ug dose 60 μmol L 60 #mg BID [003] 60 -#.# ± [002] 60 MBq 60 oxycodone CR 60 mg dose 60 μg kg 60 p = .# [002] 60 FOLFOX 60 5-FU/LV 60 #mg BID [001] 60 randomization 60 mg ustekinumab 60 highest tertile 59 nonobese 59 adjunctive placebo 59 mg/m2 59 QTcF 59 biochemical relapse 59 CR nPR 59 plus methotrexate 59 hip BMD 59 HCV genotype 59 ‰ ¥ 59 PaO 2 59 preoperative 59 underwent resection 59 patients evaluable 59 HBeAg positive 59 hours postdose 59 leukopenia 59 antiretroviral naive 59 % Confidence Interval 59 Exclusion criteria 59 CI -#.# 59 underwent CABG 59 peginterferon alfa 2a 59 LVEF 59 timepoint 59 mg 59 events AEs 58 MADRS score 58 LPV r 58 timepoints 58 Median PFS 58 progression TTP 58 pmol L 58 achieved PASI 58 mm Hg 58 comparator arm 58 virologic failure 58 HIV uninfected 58 PREZISTA ritonavir 58 lispro 58 treatment naïve genotype 58 nondiabetic patients 58 median PFS 58 8mg/kg 58 pg ml 58 ng ml 58 antiretroviral naïve 58 prespecified 58 achieved ACR# 58 nonfatal MI 58 randomisation 58 biochemical recurrence 58 multivariate analysis 58 evaluable subjects 58 ng dL 58 methotrexate monotherapy 58 saline placebo 58 peginterferon alfa 2b 58 Primary endpoints 58 nondiabetic 58 histologically confirmed 58 placebo dexamethasone 58 mL 58 lamivudine refractory patients 58 mL kg 58 treatment naive genotype 58 FOLPI 58 mcg linaclotide 58 coronary revascularization 58 preoperatively 58 stage IIIB 58 severe neutropenia 58 stage IIIb IV 58 HCV infected 58 nonrandomized 58 Secondary endpoints included 58 insulin detemir 58 posttransplant 58 systolic BP 58 Sprague Dawley rats 58 male Wistar rats 58 ribavirin RBV 57 FOLFIRI alone 57 generalized edema 57 receiving ISENTRESS 57 placebo p = 57 sd = 57 postop 57 HBeAg negative patients 57 MACCE 57 nasopharyngitis 57 genotypic resistance 57 mmHg 57 hypophosphatemia 57 LEXIVA r 57 TEAEs 57 μg mL 57 Secondary endpoints include 57 receiving VICTRELIS 57 retrospective cohort 57 #mg/kg [002] 57 Flu Cy 57 univariate analysis 57 Baseline characteristics 57 mcg 57 #mg/m# [001] 57 g dL 57 ng mL 57 ug kg 57 copies mL 57 adefovir treated 57 desvenlafaxine succinate 57 tirofiban 57 intramuscularly 57 CC genotype 57 euthyroid 57 ascending doses 57 CR CRu 57 virological response 57 chlorambucil 57 Wistar rats 57 Peg IFN 57 GnRH agonist 57 prospectively randomized 57 CSBM 57 #mg/m# [002] 57 IFN alfa 57 HCV genotype 1 57 partial remissions 57 log# copies mL 57 HBeAg seroconversion 57 prospectively defined 57 CI #.#-#.# [001] 57 certolizumab 56 mcg mL 56 histologically proven 56 microbiologically evaluable 56 p ≤ 56 mL/min/#.# m2 56 XELOX 56 mg/m2/day 56 dosing cohorts 56 NMIBC 56 cohort 56 irbesartan 56 preintervention 56 creatinine ratio 56 microg 56 laboratory abnormalities 56 Secondary endpoints 56 mCRC patients 56 infliximab monotherapy 56 lamivudine monotherapy 56 definite stent thrombosis 56 genotyped 56 relapsed MM 56 underwent surgical resection 56 DAS# scores 56 mg qd 56 plus dexamethasone 56 efavirenz EFV 56 piperacillin tazobactam 56 confidence intervals CIs 56 PASI scores 56 discontinuations due 56 nadroparin 56 unfractionated heparin 56 randomized #:#:# 56 active comparator 56 cystectomy 56 CI #.#-#.# [002] 56 eptifibatide 56 nM 56 FOLFIRI 56 lowest tertile 56 ipsilateral 56 dexamethasone 56 contralateral 56 hemodynamically significant 56 nonsignificant difference 56 plus ribavirin 56 DLTs 56 Postoperative 56 logistic regression analysis 56 PSA nadir 56 mL/min/#.# m 2 56 liver transplant recipients 56 octreotide LAR 56 ropivacaine 56 ipsilateral stroke 56 statistically significant reduction 56 ovariectomized 56 ng dl 56 randomized clinical 56 amoxicillin clavulanate 56 GH deficiency 56 alanine aminotransferase 56 nulliparous women 56 lymphocytosis 56 #mg BID [002] 56 adalimumab 56 flutamide 56 Complication rates 56 mCi 56 anemia hemoglobin 56 ALT flares 56 mg dL 56 weekly subcutaneous injections 56 hypokalemia 56 mCi kg 56 HCV SPRINT 56 pT3 56 Operative mortality 56 HbA1c levels 56 milliliters mL 56 trials RCTs 56 dose dose escalation 56 plasma uric acid 56 breast carcinoma 56 NSTE ACS 56 -#.# log# 56 nucleoside naive 56 OADs 55 mg m 55 Elitek 55 placebo controlled clinical trials 55 Preoperatively 55 diameter stenosis 55 colorectal adenoma 55 FOLFOX4 55 ABC/3TC 55 virologic breakthrough 55 nmol 55 TDF FTC 55 serum HCV RNA 55 hsCRP levels 55 achieved sustained virological 55 APTIVUS r 55 placebo controlled 55 tapentadol ER 55 umol L 55 interquartile range IQR 55 tolterodine ER 55 KRAS mutations occur 55 Q2W 55 intra articular injection 55 pooled comparator 55 3mg/kg 55 postoperative 55 RLAI 55 TURBT 55 ACTEMRA TM 55 RECIST criteria 55 copies ml 55 concomitant medications 55 adjunctive ABILIFY 55 HIV RNA 55 dapagliflozin plus 55 μg dose 55 nonsignificant 55 peginterferon alfa 2a #KD 55 tipranavir r 55 Viread Emtriva Sustiva 55 composite endpoint 55 â ‰ ¥ 55 rFSH 55 BMI ≥ 55 abacavir lamivudine 55 PRADAXA #mg 55 serum concentrations 55 prospectively stratified 55 β blockers 55 PREZISTA r 55 multicenter randomized 55 QRS duration 55 MetS 55 mg q#h 55 Index CDAI 55 Kaplan Meier analysis 55 clinically meaningful improvement 55 mIU mL 55 thromboembolic events 55 myocardial infarction MI 55 moderately emetogenic 55 CIMZIA TM certolizumab pegol 55 solifenacin 55 chronic HCV genotype 55 REBETOL 55 undetectable HCV RNA 55 plus prednisone 55 Psoriasis Area 55 CsA 55 tertile 55 symptomatic BPH 55 undergone splenectomy 55 EDSS score 55 mg/m2 IV 55 ascending dose 55 neoadjuvant 55 kg -1 55 lumbar spine BMD 55 HCV RESPOND 2 55 HIV seronegative 55 surgically resected 55 fatigue asthenia 55 serum testosterone 55 baseline HbA1c 55 subtrochanteric 55 statistically significant improvement 55 histologically 55 non splenectomized 55 EURIDIS 55 mg Lucentis 55 endoscopic remission 55 serum IGF 55 thromboembolic 55 hepatectomy 55 HBeAg 55 achieved statistical significance 55 r = 55 tertiles 55 p = #.# [003] 55 alanine aminotransferase ALT 55 virological failure 55 mg simvastatin 55 peg IFN 55 virologic response 55 intravenous bolus 55 spontaneous bowel movements 55 mild renal insufficiency 55 CRp 55 Partial Responses 55 mg RDEA# 55 ≤ 55 prospectively evaluated 55 cirrhotic 55 nadolol 55 μg doses 55 x ULN 55 nmol L 55 null responder HCV 55 nmol liter 55 binary restenosis 55 hypogonadal men 55 ug mL 55 pmol liter 55 q#h 55 administered subcutaneously 55 ECOG PS 55 mitoxantrone 55 cells mcL 55 recurrent VTE 55 NNRTI resistance 55 doxorubicin cyclophosphamide 55 detrusor 55 doxorubicin docetaxel 55 IU ml 55 chemoradiation therapy 55 locoregional 55 Acute Coronary Syndromes ACS 55 intraperitoneal 55 stomatitis 54 morphometric vertebral fractures 54 CHOP chemotherapy 54 pharmacokinetics PK 54 Apidra ® 54 NPH insulin 54 mg administered orally 54 Helicobacter pylori eradication 54 elevated transaminases 54 XIENCE V demonstrated 54 ANCOVA 54 interferon alfa 2a 54 PEG IFN 54 nephrectomy 54 ACR Pedi 54 nodal metastases 54 logistic regression model 54 monotherapy 54 nonmetastatic 54 creatinine clearance 54 non inferiority 54 androgen deprivation 54 intraocular inflammation 54 mcg dose 54 IQR 54 ^ sup 54 mg subcutaneously 54 TMC# r 54 BARACLUDE ® 54 periprocedural 54 paclitaxel eluting stents 54 androgen suppression 54 unresectable HCC 54 postmenopausal osteoporotic women 54 detrusor overactivity 54 lung metastases 54 CCyR 54 aspartate aminotransferase AST 54 intermittent dosing 54 ALT elevations 54 radiotherapy RT 54 mol L 54 fluorouracil leucovorin 54 placebo p 54 statistically significant differences 54 Free Survival PFS 54 #mg/day [002] 54 NNT = 54 multivariate analyzes 54 low dose cytarabine 54 oral allopurinol 54 paroxysmal AF 54 PCa 54 achieved CCyR 54 severe exacerbations 54 tamsulosin 54 Brief Psychiatric 54 Median survival 54 male Sprague Dawley 54 plus MTX 54 Folfox 54 RBC transfusion 54 IIIa inhibitor 54 statistically significant p = 54 mg tid 54 retrospective observational study 54 T2DM 54 advanced adenoma 54 papillary renal cell carcinoma 54 symptomatic VTE 54 QD dosing 54 biventricular repair 54 sinus rhythm 54 perioperatively 54 seminal vesicle invasion 54 peginterferon 54 mm Hg diastolic 54 metformin monotherapy 54 prior relapsers 54 CDAI 54 diastolic BP 54 postoperative complication 54 IPSS 54 transurethral resection 54 nodular partial response 54 intraperitoneally 54 undergoing coronary angiography 54 NYHA class 54 ejection fractions 54 HBeAg negative 54 nicardipine 54 cGy 54 ml min 54 NHANES III 54 Researchers randomly assigned 54 mcg kg REBETOL 54 dalteparin 54 mmol L 54 seroconverted 54 homozygotes 54 Postoperatively 54 QTc 54 bortezomib refractory 54 experienced virologic failure 54 sUA 54 randomized placebo controlled 54 plus gemcitabine 54 seropositivity 54 DMARD 54 etanercept 54 subsample 54 patientswith 54 stent binary restenosis 54 IU mL 54 atopic 54 pneumonectomy 54 left ventricular LV 54 noninferior 54 5FU 54 intravitreal injections 54 prospective observational 54 TT genotype 54 serum HBV DNA 54 R# #mg BID 54 prepubertal 54 intratympanic 54 CrCl 54 abciximab 54 -#.# mg dL [002] 54 FluCAM arm 54 Main Outcome Measures 54 isoproterenol 54 CANCIDAS 54 FLT3 ITD 54 metastatic GIST 54 left ventricular systolic 54 PegIFN 54 q# 54 reinfarction 54 ceftazidime 54 statistically significant p 54 LV ejection fraction 54 dysuria 54 ATACAND 54 pegylated liposomal doxorubicin 54 HbA 1c levels 54 locoregional disease 54 blind randomized 54 baseline FEV 54 de novo AML 54 plasma glucose 54 RRMS patients 54 fasting triglyceride levels 54 univariate analyzes 54 min -1 54 concurrent chemoradiation 54 randomized multicenter 54 IIIa inhibitors 54 pimecrolimus cream 54 Median progression 54 melphalan prednisone 54 unfractionated heparin UFH 54 HAM D# scores 54 mcg doses 54 mM 54 HBsAg 54 CIMZIA TM 54 DAS# CRP 54 headache nasopharyngitis 54 log# 54 hematologic toxicity 54 % CI #.#-#.# [004] 54 tipranavir ritonavir 54 lymphadenectomy 53 dosing cohort 53 SSRI citalopram 53 squamous histology 53 non valvular atrial 53 μM 53 Lucentis monotherapy 53 patients undergoing CABG 53 daily subcutaneous injections 53 EDSS scores 53 seroconversion 53 Kaplan Meier estimate 53 concomitant AEDs 53 splenectomized patients 53 prior chemotherapy regimens 53 F FDG PET 53 multivariable adjusted 53 caspofungin 53 VT VF 53 THIS STUDY 53 leucopenia 53 q#d 53 bosentan 53 adenotonsillectomy 53 NSTEMI 53 PANSS scores 53 posaconazole 53 advanced adenomas 53 lacunar 53 heterozygotes 53 #.#g/day 53 ACR# response 53 pruritis 53 mmHg diastolic 53 cisplatin vinorelbine 53 statistically significant 53 mg eq 53 pericardial effusion 53 randomized crossover 53 FOLFOX4 alone 53 femoral neck BMD 53 débridement 53 remission induction 53 mRNA expression 53 HCV RNA 53 docetaxel pretreated 53 intratumoral 53 achieved sustained virologic 53 plus GP IIb 53 receiving PEGINTRON 53 covariates 53 lumen diameter 53 incontinence episodes 53 underwent radical prostatectomy 53 #mg q8h 53 Asymptomatic 53 tibiofemoral 53 femoral shaft fracture 53 refractory NSCLC 53 PREZISTA r arm 53 μg ml 53 continuous intravenous infusion 53 mg BID dose 53 ritonavir boosted 53 carboplatin paclitaxel 53 retrospectively analyzed 53 genotype 1b 53 fibrinolytic therapy 53 mIU ml 53 mild renal impairment 53 affective psychosis 53 μg L 53 antral 53 nonresponders 53 RGT arm 53 primary patency 53 interferon alfa 2b 53 XIENCE V PROMUS Stent 53 IFN α 53 LAB GHRH 53 mcg Albuferon 53 Adverse events 53 #.#mg/dL 53 nondepressed 53 NIH CPSI 53 #mg dosing 53 intravenous dosing 53 achieved mucosal healing 53 daunorubicin 53 METHODS 53 multivariable analysis 53 dose regimens 53 bolus dose 53 nonmetastatic prostate cancer 53 μg d 53 cervical lymph nodes 53 naïve HCV 53 MIC# [001] 53 events SAEs 53 antiarrhythmic drug 53 hepatic metastases 53 alfa 2a 53 mmHg systolic 53 pyrexia 53 detectable HCV RNA 53 C#BL 6 mice 53 mITT 53 ANOVA 53 mCi m 2 53 oral diclofenac 53 mg/# hours 53 HGPIN 53 resected 53 splenectomized 53 nonoperative 53 dacarbazine 53 estimated glomerular filtration 53 budesonide pMDI 53 radical cystectomy 53 primary endpoint 53 mesalamine granules 53 saline injections 53 mg m² 53 null responder 53 treated nonoperatively 53 cerebrovascular events 53 adefovir 53 ritonavir boosted lopinavir 53 mITT population 53 ALT elevation 53 microgram kg 53 asthma exacerbation 53 nab paclitaxel 53 dosage regimens 53 relapsers 53 Platelet counts 53 ertapenem 53 HBeAg positive patients 53 pharmacokinetic parameters 53 femoral neck fracture 53 SBM frequency 53 distant metastases 53 elevated LDH 53 serum leptin 53 bivariate analyzes 53 acromegalic patients 53 REYATAZ r 53 Cmax 53 restenotic lesions 53 secondary endpoint 53 Target Lesion Revascularization TLR 53 nasopharyngitis headache 53 retrospectively reviewed 53 remission CR 53 corticosteroid dose 53 telaprevir dosed 53 reintervention 53 chemoradiotherapy 53 progressive PsA 53 HSCT 53 recurrent acute pancreatitis 53 acneform rash 53 subscale scores 53 neutrophil counts 53 intima media thickness 53 undergone radical prostatectomy 53 demonstrated statistically significant 53 hepatic enzyme 53 multicenter randomized controlled 53 HRCT 53 highly emetogenic 53 GP IIb IIIa 53 events MACE 53 ± SEM 53 titrated glipizide 53 BMD measurements 53 liver biopsies 53 ipsilateral breast 53 randomized blinded 53 VFEND 53 MMSE score 53 μg liter 53 covariate 53 multicentre 53 oral rivaroxaban 53 lymphopenia 53 moderate renal impairment 53 parous women 53 hypoglycemic events 53 antithymocyte globulin 53 preoperative chemotherapy 53 #μg [002] 53 DMARD therapy 53 EBRT 53 GG genotype 53 locoregional recurrence 53 hemodialysis patients 53 neurologic progression 53 postprocedure 53 HBV DNA 53 premenopausal 53 nonoperative treatment 53 oral prednisone 53 adrenalectomy 53 free survival PFS 53 kcal d 53 dose cohort 53 substudy 53 infarct 53 low dose dexamethasone 53 angiotensin converting enzyme inhibitor 53 metastatic RCC 53 clodronate 53 receiving highly emetogenic 53 hypercholesterolemic 53 rhGH 53 mucositis stomatitis 53 radical nephrectomy 53 placebo controlled dose escalation 53 total knee arthroplasty 52 tolterodine 52 macroalbuminuria 52 ALT normalization 52 iodixanol 52 blind placebo 52 neonates 52 transplant ASCT 52 adriamycin 52 intact parathyroid hormone 52 hypogonadal 52 cytologically confirmed 52 liver histology 52 pCR 52 genotype 52 ARCOXIA 52 WOMAC scores 52 postvaccination 52 daily Infergen 52 recanalization 52 intravesical 52 oral antidiabetic medication 52 % CI #.#-#.# [005] 52 SAEs 52 urothelial carcinoma 52 CLL SLL 52 placebo PBO 52 recurrent glioblastoma multiforme 52 Multivariate analysis 52 peripheral blood mononuclear 52 mg/m2 administered 52 ziprasidone 52 salmeterol fluticasone 52 rizatriptan 52 Left Ventricular Ejection Fraction 52 conjugated equine estrogen 52 randomized controlled trial 52 plus glycoprotein IIb 52 NYHA functional class 52 PegIFN RBV 52 primary percutaneous coronary 52 multivariate adjustment 52 fluorouracil 52 hepatitis C genotype 52 adjuvant tamoxifen 52 generalized tonic clonic seizures 52 IV NSCLC 52 uM 52 % CI #.#-#.# [001] 52 docetaxel prednisone 52 mg/# h 52 splenic 52 HbA 1c 52 cytogenetic abnormalities 52 P ≤ 52 receiving INTRON 52 femoral fracture 52 normothermic 52 intravesical therapy 52 REYATAZ ritonavir 52 p = .# [001] 52 nonfatal myocardial infarction 52 mIU L 52 prespecified secondary 52 mg Androxal 52 pruritus 52 lumbar spine bone 52 Kaplan Meier curves 52 mg orally 52 submucosal 52 aspartate aminotransferase 52 gadolinium enhanced 52 left ventricular dysfunction 52 serum phosphorus 52 thromboembolic complications 52 thrombocytopenic 52 advanced neoplasia 52 subscore 52 mL min 52 palmar plantar 52 pegylated interferon 52 #mg dosing group 52 histological subtype 52 beta blocker therapy 52 ischemia driven 52 CIMZIA R 52 conjunctival hyperemia 52 observational cohort study 52 univariate 52 rapid virologic response 52 -#.# ± [001] 52 subcutaneous doses 52 operable breast cancer 52 Fasting plasma glucose 52 haematologic 52 revascularizations 52 beclomethasone dipropionate 52 histologic 52 glulisine 52 virologic response EVR 52 hypomagnesemia 52 vertebral fracture 52 #.#mg/kg [002] 52 syndromal 52 mitoxantrone plus 52 external beam radiotherapy 52 COPD exacerbation 52 overt nephropathy 52 pulmonary arterial 52 intraperitoneal injection 52 mg dosed twice 52 hypocalcemia 52 pheochromocytoma 52 treatment emergent adverse 52 atheroma volume 52 #Gy 52 Hypomagnesemia occurred 52 Peginterferon Alfa 2a 52 log# reduction 52 insulin glargine 52 debulking surgery 52 Hb A1C 52 achieving PASI 52 hepatic resection 52 vastus lateralis 52 paclitaxel carboplatin 52 ribavirin therapy 52 underwent percutaneous coronary 52 microbiological eradication 52 prednisone prednisolone plus 52 KRAS wild 52 vinorelbine 52 Pegasys plus Copegus 52 diabetes mellitus DM 52 rFVIIa 52 Taxus Stent 52 dyspnea 52 Gy 52 DCCT 52 completely resected 52 mm Hg systolic 52 TAXUS p value 52 lamivudine 52 lenalidomide dexamethasone 52 sociodemographic characteristics 52 del 5q 52 estramustine 52 iniparib BSI 52 arterial thromboembolic events 52 subscales 52 parasitaemia 52 probands 52 corrected QT interval 52 patients receiving ERBITUX 52 BEACOPP 52 SVR# 52 #mmHg [001] 52 urodynamic 52 sham injections 52 plus medroxyprogesterone acetate 52 unstable angina pectoris 52 ml kg 52 undergoing radical cystectomy 52 BoNTA 52 dose cohorts 52 Thrombolysis 52 remifentanil 52 Subgroup analysis 52 febrile neutropenia 52 airway responsiveness 52 distant metastasis 52 retrospective cohort study 52 pT2 52 SBMs 52 esophageal carcinoma 52 death reinfarction 52 TIMP 52 darunavir ritonavir